Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07823790

ONO-4915 in Patients With Primary Sjogren's Disease

To evaluate the efficacy and safety of ONO-4915 in patients with primary Sjogren's disease

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age (at the time of informed consent): >=18 and <75 years
  • Patients who meet the criteria for primary Sjogren's disease defined by the 2016 ACR/EULAR Classification Criteria for Primary Sjogren's Syndrome
  • Patients with positive anti-SS-A/Ro antibody in the screening period
  • Patients with ESSPRI score of >=5 and dry symptom score of >=5 in the screening period
  • Patients with stimulated salivary secretion rate of >=0.1 mL/min by the Saxon test in the screening period.
  • Patients diagnosed with primary Sjogren's disease within 10 years

Exclusion criteria

  • Patients with other concurrent autoimmune diseases
  • Patients who may overlap with the clinical symptoms of primary Sjogren's disease or interfere with the evaluation of the clinical symptoms
  • Patients with any disease that may interfere with the evaluation of dry symptoms of primary Sjogren's disease
  • Patients with any disease that may interfere with the evaluation of pain of primary Sjogren's disease
  • Patients with severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, psychiatric, cardiac, endocrine, neurologic, or cerebral disease unrelated to the primary disease
  • Patients with current malignancy or history of malignancy within 5 years before the start of screening
  • Patients with active infection

Treatment and study plan

ONO-4915

Drug

Subcutaneous administration

Placebo

Drug

Subcutaneous administration

Primary outcomes

  1. Change from baseline in the Patients with EULAR Sjogren's Syn drome Patient Reported Index (ESSPRI) score at Week 24

    Time frame: up to week 24

    Patient-reported assessment of dryness, fatigue, and pain, each scored from 0 to 10. The total ESSPRI score is calculated as the mean of the three domain scores and ranges from 0 to 10, with higher scores indicating worse symptoms.

Secondary outcomes

  1. ESSPRI total score

    Time frame: up to week 32

    Patient-reported assessment of dryness, fatigue, and pain, each scored from 0 to 10. The total ESSPRI score is calculated as the mean of the three domain scores and ranges from 0 to 10, with higher scores indicating worse symptoms.

  2. Subjective symptom score of Sjogren's disease

    Time frame: up to week 32

    Each symptom is scored daily on a numerical scale, with higher scores indicating worse symptoms.

  3. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) score

    Time frame: up to week 32

    Symptoms are evaluated across 12 organ/system domains using a 4-point scale (0 = no activity to 3 = severe activity). Each domain score is weighted according to its clinical importance, and the weighted scores are summed to yield a total score ranging from 0 to 123, with higher scores indicating greater disease activity.

  4. Joint counts

    Time frame: up to week 32

  5. Physician's Global Assessment (PGA) score

    Time frame: up to week 32

    Evaluated by physician on a numerical scale. Higher scores indicate worse symptoms.

  6. Stimulated salivary secretion rate

    Time frame: up to week 24

  7. Unstimulated salivary secretion rate

    Time frame: up to week 24

  8. Tear secretion rate

    Time frame: up to week 24

  9. Adverse events and adverse reactions

    Time frame: up to week 32

  10. Number of participants with abnormal laboratory tests (hematology)

    Time frame: up to week 32

  11. 12-lead electrocardiogram (Heart rate)

    Time frame: up to week 24

  12. Number of participants with abnormal Chest X-ray tests

    Time frame: up to week 24

  13. Body Weight

    Time frame: up to week 32

  14. Number of participants with abnormal laboratory tests (Immunological test)

    Time frame: up to week 32

  15. Rate of PD-1/CD19 occupancy

    Time frame: up to week 24

  16. Serum CXCL13 concentration

    Time frame: up to week 32

  17. T-cell markers (immunophenotyping)

    Time frame: up to week 32

  18. Anti-SS-A/Ro antibody titer

    Time frame: up to week 32

  19. Plasma ONO-4915 concentration

    Time frame: up to week 32

  20. Number of Participants with anti-ONO-4915 antibody

    Time frame: up to week 24

  21. Anti-SS-B/La antibody titer

    Time frame: up to week 32

  22. Anti-centromere antibody titer

    Time frame: up to week 32

  23. Antinuclear antibody titer

    Time frame: up to week 32

  24. Concentration of Rheumatoid factor

    Time frame: up to week 32

  25. ESSPRI domain scores

    Time frame: up to week 32

    Scores for the dryness, pain, and fatigue symptoms comprising the ESSPRI. Higher scores indicate worse symptom severity.

  26. ESSPRI responder rate

    Time frame: up to week 32

  27. Serum BAFF concentration

    Time frame: up to week 32

  28. B-cell markers (immunophenotyping)

    Time frame: up to week 32

  29. Number of participants with abnormal laboratory tests (blood biochemistry)

    Time frame: up to week 32

  30. Number of participants with abnormal laboratory tests (urinalysis)

    Time frame: up to week 32

  31. Number of participants with abnormal laboratory tests (coagulation tests)

    Time frame: up to week 32

  32. 12-lead electrocardiogram (PR interval)

    Time frame: up to week 24

  33. 12-lead electrocardiogram (RR interval)

    Time frame: up to week 24

  34. 12-lead electrocardiogram (QRS duration)

    Time frame: up to week 24

  35. 12-lead electrocardiogram (QT interval)

    Time frame: up to week 24

  36. 12-lead electrocardiogram (QTcF Interval)

    Time frame: up to week 24

  37. Blood Pressure

    Time frame: up to week 32

  38. Pulse Rate

    Time frame: up to week 32

  39. Body Temperature

    Time frame: up to week 32

Study contacts

Contact information is provided by the study sponsor or research team.

International Clinical Trial Support Desk

CONTACT

[email protected]

+17162141777(Standard)

North America Clinical Trial Support Desk

CONTACT

[email protected]

+18665877745(Toll-Free)

Sponsors and collaborators

Lead sponsor

Ono Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Phase II Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Study in Patients With Primary Sjogren's Disease to Evaluate the Efficacy and Safety of Subcutaneously Administered ONO-4915

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Sep 16, 2026
Registry last updated
Sep 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.